Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

TCRX

TScan Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1783328Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$10.0M
Net Income FY2025
$(130.0M)
EPS (Basic, as reported)
$-1.00
Net Margin FY2025
-1256.8%
ROE FY2025
-105.4%
Total Equity
$123.0M
Shares Out
24M
Business description

TScan Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 1 → 10 +58.5% CAGR
Fiscal yearFY2020FY2021⚑FY2022⚑FY2023⚑FY2024FY2025
Revenue1101421310
Research & development(21)(45)(60)(88)(107)(114)
General & administrative(7)(14)(20)(26)(30)(32)
Total operating expenses(27)(59)(80)(115)(138)(146)
Operating income(26)(49)(67)(93)(135)(136)
Interest expense——(1)(4)(4)(3)
Other income (expense), net—00476
Income tax expense—————0
Net income(26)(49)(66)(89)(127)(130)
EPS — basic—($4.17)($2.75)($1.36)($1.14)($1.00)
EPS — diluted—($4.17)($2.75)($1.36)($1.14)($1.00)
Shares outstanding — basic (M)—122466112130
Shares outstanding — diluted (M)—122466112130
  • ⚑ Weighted-average shares changed ×2.00 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×2.75 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×1.70 between FY2023 and FY2024 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.